MASCT-I Combined With PD1 and Apatinib in the Treatment of Tissue Sarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sarcoma
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 14 years and 70 years
- Gender
- Both males and females
Description
This is a single-center,Exploratory Research for evaluating the efficacy of MASCT-I With PD1 Antibody and Apatinib in patients with advanced Advanced Osteosarcoma and Soft Tissue Sarcoma and preliminarily assessing the preliminary observation of immune response and safety. About 20 cases of adult pa...
This is a single-center,Exploratory Research for evaluating the efficacy of MASCT-I With PD1 Antibody and Apatinib in patients with advanced Advanced Osteosarcoma and Soft Tissue Sarcoma and preliminarily assessing the preliminary observation of immune response and safety. About 20 cases of adult patients are to be recruited. The patients were randomly divided into two groups. One group received MASCT-I A+PD1 antibody+Apatinib treatment, the other group received MASCT-I B+PD1 antibody+Apatinib treatment. In combination with MASCT-I, the dosage and cycle of PD1 antibody and Apatinib did not change. MASCT-I A and MASCT-I B are mainly administered with different frequencies of MASCT-I. After treatment, patients were assessed by CT imaging every 8 weeks. If the disease progressed or could not be tolerated, or when the end of treatment (104 weeks), the treatment would be discontinued, whichever happened first.
Tracking Information
- NCT #
- NCT04074564
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon